The decision means perhaps tens of thousands of additional people can get tested at Lilly’s drive-thru, including people who work in grocery stores, pharmacies, banks and other places listed by the state as essential.
In a deal that could eventually be worth close to a billion dollars, Eli Lilly and Co. is teaming with a British biopharmaceutical company in one of the hottest areas in medical research.
State officials have taken sharp criticism in the last week for the slow pace of testing. Through Tuesday, the Indiana State Department of Health had conducted 193 tests, out of which 39 were presumed positive.
Increasingly, as the planet warms, pressure is building from environmentalists, investors, consumers and the general public for corporate America to do something about it.
The Indianapolis-based drugmaker said it will combine its capability for quickly developing antibodies with AbCellera’s “rapid pandemic response platform,” with the goal of getting a treatment into clinics for human testing within four months.
Indianapolis-based Lilly, the 12th largest employer in Indiana with 10,600 workers in the state, said it didn’t have a specific timeline for how long the precaution would last.
A growing number of employers have restricted international travel and are now considering what they might need to do within the U.S.
The Indianapolis-based drugmaker exceeded analyst expectations for both profit and revenue during the most recent quarter.
Eli Lilly and Co. said it considered sites in Indianapolis and Pennsylvania but chose North Carolina for quality of life, cost of operations and geographical diversity.
The Indianapolis drugmaker quietly terminated a collaboration with NextCure Inc. after spending $40 million on an up-front fee and equity investment, and with little to show from the partnership.
Under fire over insulin prices, the Indianapolis-based drugmaker said Tuesday morning it is introducing lower-priced versions of its Humalog KwikPen and Humalog Junior KwikPen.
Analysts have said that Dermira’s lead pipeline product, lebrikizumab, has the potential to be the best in class among a wave of similar antibodies to treat eczema.
Alimta is Lilly’s third-best-selling drug, with global sales of $2.1 billion last year. The court ruling stops a Canadian competitor from launching a generic version of the drug before its patent expires in 2022.
For the Lilly Endowment, a good year means it’s time to cash in.
Under fire from politicians, patients and health care advocates over the price of insulin, Eli Lilly and Co. announced a campaign Thursday morning to raise awareness of cost-saving options for the drug.
The pharmaceutical giant says it needs additional manufacturing capacity to keep up with demand for current medicines and new drugs expected to emerge from its pipeline.
Digging through old data to salvage a seemingly failed Alzheimer’s drug paid off big time for Biogen Inc., but at least one of its rivals has no plans to follow suit.
Eli Lilly and Co. easily topped earnings expectations in the third quarter, but shares in the Indianapolis-based drug company tumbled nearly 5 percent Wednesday morning.
Seven months after clinical trials for a promising Alzheimer’s drug were halted and the treatment was declared a failure, a new analysis suggests it was actually effective, and the company that makes it plans to move forward in securing federal approval.
The drug, called pegilodecakin, had been seen as a promising treatment for one of the deadliest types of cancer, and was the lead product in Lilly’s $1.6 billion acquisition of Armo BioSciences last year.
